Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer
Status:
Recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
AMBRE is a phase III study comparing two standard treatments as initial metastatic treatment
in ER+/HER2- breast cancer (BC) patients with visceral metastasis and high burden disease:
Chemotherapy and combination of endocrine therapy with abemaciclib.